explore -WSS

explore

author：leisure time 2025-10-02 21:05:52 - browse：396

Adam's take main illustration — Molly Ferguson/STAT

Happy Groundhog Day eve. Some takes and thoughts on Bluebird Bio’s quest for gene therapy profits, a reality check on Vertex’s highly touted pain drug, and more ADC investor FOMO.

Bluebird and the case for gene therapy profits

Genetic treatments that are potential cures for inherited diseases are a huge medical advance, but can these transformational (and expensive) products become a profitable business? I’m not sure anyone knows yet for sure, but pay attention to Bluebird Bio over the next year for some clues.

Bluebird is unique among the biotech and pharma companies selling gene therapies (or CRISPR-based medicines) today because it has no other marketed products. With the recent approval of Lyfgenia for sickle cell disease (cost: $3.1 million), Bluebird sells three gene therapies. The other products are Zynteglo for beta thalassemia ($2.8 million) and Skysona for cerebral adrenoleukodystrophy ($3 million). It’s a pure-play commercial gene therapy business. It’s not even trying to develop additional gene therapies currently. R&D expenses are tied to gathering long-term data on its existing products.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： RSV injection headlines need to be accurate for good uptake

knowledge

WSS

Experts study whether long Covid risk adds up with each reinfection

First U.S. drug developed to treat liver disease MASH is approved

IVG is promising — but it won’t replace IVF quite yet

How to save health care price transparency rules

WHO recommends second malaria vaccine

Lawsuit highlights wrinkle for disputes over surprise medical bills

Wikipedia

explore

Bluebird and the case for gene therapy profits

entertainment

State Dept. review finds Biden bears some blame for Afghanistan failures

RSV injection headlines need to be accurate for good uptake

New air purifier tech could be key to improving indoor air quality

FDA advisers back CAR

Sports medicine is finally prioritizing gender equality

What will Novo Nordisk's VC do with its influx of cash?

Alkermes shareholders re

Will an HIV vaccine ever be a reality?

Medicare details structure of new drug price negotiation program

RaDonda Vaught links Vanderbilt hospital issues to patient death

hotspot

How many hemophilia patients actually want gene therapy?

Steward Health Care Massachusetts hospitals face fiscal disaster

Flu, Covid vaccination rates decline, new survey data show

Medicare innovation center doesn’t save money, experts say

John Green on his newest strategy for fighting tuberculosis

How to save health care price transparency rules

knowledge

focus

knowledge

hotspot